NCT03731026 - The LightPath® and 68Ga-RM2 in Breast Cancer Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2018

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions

Breast Cancer

Interventions

COMBINATION_PRODUCT

LightPath® Imaging System and 68Ga-RM2

"Imaging System:The LightPath® Imaging System is an in vitro diagnostic device which has CE mark in Europe, in line with In Vitro Diagnostic Medical Devices 98/79/EC (post-marketing study).~Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical."

DRUG

68Ga-RM2

Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.

Trial Locations (1)

SE1 7EH

Guy's and St Thomas' NHS Foundation Trust, London